Wire · opportunities
New HER2-Directed Therapies Reshape First-Line Treatment of Gastroesophageal Adenocarcinoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
The FDA approved zanidatamab-based regimens as a new first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma following phase 3 trial results showing improved overall survival compared to trastuzumab plus chemotherapy. Treatment strategies now emphasize HER2 expression and PD-L1 status for therapy selection, with repeat biopsy recommended after progression to guide sequencing.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 27 Sep 2026 and 8 Oct 2026.
◆ ◆ The Wire takeaway
You need to update your treatment protocols to integrate zanidatamab as a front-line option for HER2-positive gastroesophageal adenocarcinoma. Prioritise tools and diagnostics that support HER2 and PD-L1 status reassessment to stay competitive in treatment sequencing.
◆ Coverage
2 sources · first reported 27 Sep 2026 · latest 8 Oct 2026
◆ Related on Wire
◆ Topics